CRANFORD, N.J., Could 18, 2022 /PRNewswire/ — Citius Prescription drugs, Inc. (“Citius” or the “Corporation”) (Nasdaq: CTXR), a late-phase biopharmaceutical enterprise establishing and commercializing to start with-in-course crucial care goods, these days introduced that it will current at the H.C. Wainwright Worldwide Investment decision Meeting staying held Might 23-26, 2022. Leonard Mazur, Chairman and CEO of Citius, will discuss the Firm’s modern business developments and impending milestones.
|
H.C. Wainwright Worldwide Trader Conference |
|
|
Presentation day and time: |
Tuesday, May perhaps 24, 2022 at 11:00 a.m. ET |
|
Area: |
Digital and at the Fontainebleau Miami Beach Hotel, Miami Beach front, Florida |
|
Registration: |
Visit the conference site for in-person or virtual registration |
|
Live webcast: |
Register listed here to check out |
|
Webcast replay: |
Available for 90 times |
Fascinated events may well routine 1-on-1 meetings with Citius management by registering by way of the celebration system or contacting the Firm’s trader relations staff.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical business committed to the enhancement and commercialization of 1st-in-course vital care goods, with a concentration on oncology, anti-infectives in adjunct most cancers care, exclusive prescription solutions, and stem mobile therapies. The Enterprise has two late-phase product candidates, Mino-Lok®, an antibiotic lock resolution for the therapy of patients with catheter-associated bloodstream bacterial infections (CRBSIs), which is now enrolling people in a Period 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an original sign in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Section 3 trial. Mino-Lok® was granted Rapid Track designation by the U.S. Food stuff and Drug Administration (Fda). I/ONTAK has acquired orphan drug designation by the Food and drug administration for the procedure of CTCL and peripheral T-cell lymphoma (PTCL). By way of its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell procedure derived from induced pluripotent stem cells (iPSCs) for acute respiratory situations, with a in the vicinity of-time period concentration on acute respiratory distress syndrome (ARDS) associated with COVID-19. For additional details, please go to www.citiuspharma.com.
Investor Relations for Citius Pharmaceuticals:
Ilanit Allen
Vice President, Trader Relations and Corporate Communications
T: 908-967-6677 x113
E: [email protected]
View initial material to obtain multimedia:https://www.prnewswire.com/information-releases/citius-prescribed drugs-to-existing-at-the-hc-wainwright-world-wide-expense-conference-on-may perhaps-24-2022-301549451.html
Source Citius Prescription drugs, Inc.
